Virtu Financial’s Cymabay Therapeutics CBAY Stock Holding History

Virtu Financial’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-16,328	Closed	-$243K	–	2173
2023 Q3	$243K	Buy	+16,328	New	+$216K	0.02%	595
2021 Q2	–	Sell	-19,745	Closed	-$90K	–	2199
2021 Q1	$90K	Buy	19,745 +5,469	+38%	+$29.4K	0.01%	1343
2020 Q4	$82K	Sell	14,276 -48,775	-77%	-$369K	0.01%	1113
2020 Q3	$456K	Buy	+63,051	New	+$337K	0.08%	314
2019 Q4	$66K	Buy	+33,607	New	+$126K	0.01%	1161
2019 Q3	–	Sell	-23,992	Closed	-$172K	–	1940
2019 Q2	$172K	Buy	+23,992	New	+$272K	0.01%	1052
2018 Q4	–	Sell	-19,787	Closed	-$219K	–	2079
2018 Q3	$219K	Buy	+19,787	New	+$246K	0.01%	1038
2018 Q1	–	Sell	-24,735	Closed	-$228K	–	2764
2017 Q4	$228K	Buy	24,735 +8,899	+56%	+$76K	0.01%	1530
2017 Q3	$128K	Buy	+15,836	New	+$107K	0.01%	2011

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Virtu Financial's CBAY Position: Q4 2023 in Review

Virtu Financial sold out of Cymabay Therapeutics (CBAY) in Q4 2023, closing a stake of 16,328 shares — an estimated $243K sold.

Virtu Financial first reported a position in CBAY in Q3 2017 and held it in 9 quarters. The position peaked at $456K in Q3 2020. 200 funds tracked by Wall St. Rank hold CBAY as of Q4 2023.

Virtu Financial reported no remaining Cymabay Therapeutics position as of Q4 2023 after selling out during the quarter.
Virtu Financial sold 16,328 Cymabay Therapeutics shares in Q4 2023, an estimated $243K.
Virtu Financial first reported a position in Cymabay Therapeutics in Q3 2017 and held it in 9 quarters.
Virtu Financial's Cymabay Therapeutics position peaked at $456K in Q3 2020.
200 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2023.

Based on Virtu Financial's 13F filing for Q4 2023, filed 26 Feb 2024.